Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: A meta-analysis

Mayo Clinic Proceedings

Volumn 84, Issue 3, 2009, Pages 234-242

  Doyle, James F ^a,b   Ho, Kwok M ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DOFETILIDE; PLACEBO; SOTALOL; VERAPAMIL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINUS RHYTHM; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 62749131215     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.3.234     Document Type: Article

References (43)

1. Falk RH. Atrial fibrillation [published correction appears in N Engl J Med. 2001;344(24):1876]. N Engl J Med. 2001;344(14):1067-1078.
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271(11):840-844.
3. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med. 1996;125(4):311-323.
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N.
5. Ruigómez A, Johansson S, Wallander MA, García Rodríguez LA. Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation. BMC Cardiovasc Disord. 2002;2:5. Epub 2002 Feb 26.
6. Iqbal MB, Taneja AK, Lip GY, Flather M. Recent developments in atrial fibrillation. BMJ. 2005;330(7485):238-243.
7. Savelieva I, Camm J. Update on atrial fibrillation: part II. Clin Cardiol. 2008;31(3):102-108.
8. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.
9. Opolski G, Torbicki A, Kosior DA, et al; Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126(2):476-486.
10. Carlsson J, Miketic S, Windeler J, et al; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690-1696.
11. Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al; RAte Control versus Electrical cardioversion for persistent atrial fibrillation study group. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J. 2005;149(6):1106-1111.
12. Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1998;81(8):995-998.
13. Roy D, Talajic M, Dorian P, et al; Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342(13):913-920.
14. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 1995;76(1):47-50.
15. Coceani M. Amiodarone for atrial fibrillation [letter]. N Engl J Med. 2007;356(23):2424-2426.
16. Coceani M, Mariotti R. Is amiodarone safe in heart failure [editorial]? BMJ. 2006;332(7537):317-318.
17. Thomas KL, Al-Khatib SM, Lokhnygina Y, et al. Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. Am Heart J. 2008 Jan;155(1):87-93. Epub 2007 Oct 25.
18. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;4:CD005049.
19. Channer KS, Birchall A, Steeds RP, et al. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J. 2004;25(2):144-150.
20. Vora A, Karnad D, Goyal V, et al. Control of rate versus rhythm in rheumatic atrial fibrillation: a randomized study. Indian Heart J. 2004;56(2):110-116.
21. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN; Department of Veterans Affairs CHF-STAT Investigators. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation. 1998;98(23):2574-2579.
22. Hu CL, Jiang H, Tang QZ, et al. Comparison of rate control and rhythm control in patients with atrial fibrillation after percutaneous mitral balloon valvotomy: a randomised controlled study. Heart. 2006 Aug;92(8):1096-1101. Epub 2005 Dec 30.
23. Galperín J, Elizari MV, Chiale PA, et al; GEFCA Investigators-GEMA Group, Buenos Aires, Argentina. Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther. 2001;6(4):341-350.
24. Tse HF, Lam YM, Lau CP, Cheung BM, Kumana CR. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol. 2001;28(5-6):446-450.
25. Kochiadakis GE, Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis EN, Vardas PE. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart. 2000;84(3):251-257.
26. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789-1794.
27. Singh BN, Singh SN, Reda DJ, et al; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352(18):1861-1872.
28. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42(1):20-29.
29. Singh SN, Poole J, Anderson J, et al. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. Am Heart J. 2006;152(5):974.e7-974.e11.
30. Roy D, Talajic M, Nattel S, et al; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-2677.
31. Torp-Pedersen C, Metra M, Spark P, et al; COMET Investigators. The safety of amiodarone in patients with heart failure. J Card Fail. 2007;13(5):340-345.
32. Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardiac-defibrillator for congestive heart failure [published correction appears in N Engl J Med. 2005;352(20):2146]. N Engl J Med. 2005;352(3):225-237.
33. Auricchio A, Nisam S, Klein HU. Does amiodarone increase non-sudden deaths? If so, why? J Interv Card Electrophysiol. 2000;4(4):569-574.
34. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103(10):1428-1433.
35. Køber L, Torp-Pederson C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678-2687.
36. Falk RH. Atrial fibrillation or sinus rhythm? controversy and contradiction in quality of life outcomes [editorial]. J Am Coll Cardiol. 2006 Aug 15;48(4):731-733. Epub 2006 Jul 24.
37. Atwood JE, Myers JN, Tang XC, Reda DJ, Singh SN, Singh BN. Exercise capacity in atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T). Am Heart J. 2007;153(4):566-572.
38. Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10):987-999.
39. Morales AI, Barate JD, Bruges M, et al. Acute renal toxic effect of amiodarone in rats. Pharmacol Toxicol. 2003;92(1):39-42.
40. Pollak PT, Sharma AD, Carruthers SG. Creatinine elevation in patients receiving amiodarone correlates with serum amiodarone concentration. Br J Clin Pharmacol. 1993;36(2):125-127.
41. Jong GP, Chang MH, Chang TC, et al. Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion. Chin Med J (Engl). 2006;119(24):2030-2035.
42. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med. 1998;158(15):1669-1677.
43. Marshall DA, Levy AR, Vidaillet H, et al; AFFIRM and CORE Investigators. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med. 2004;141(9):653-661.